Literature DB >> 2037679

Characterization of a reduction-sensitive factor from human plasma responsible for apparent false activity in competitive assays for antibody to hepatitis B core antigen.

E F Robertson1, J A Weare, R Randell, P V Holland, G Madsen, R H Decker.   

Abstract

Addition of reducing agents to competitive assays for antibody to hepatitis B core antigen (anti-HBc) eliminates apparent false reactivity of specimens obtained from individuals with no prior history of hepatitis B virus (HBV) infection and without other serological markers of HBV infection. We have purified and characterized a reduction-sensitive factor (RSF) isolated from the plasma of several volunteer blood donors. Column fractions were assayed fro anti-HBc by using a highly sensitive chemiluminescence assay with a detection of 0.15 Paul Ehrlich Institut units per ml at 50% inhibition. Gel filtration on Sephacryl S-300 indicated that reductant-sensitive samples possessed anti-HBc activity that was associated with immunoglobulin M (IgM), whereas reductant-stable activity was associated with IgG. Gel filtration followed by metal chelate affinity chromatography resulted in a 55-fold purification and demonstrated that RSF activity copurifies with IgM. RSF was recovered from a recombinant hepatitis B core antigen matrix and shown to be an IgM species by immunoblot. In addition, RSF activity coeluted with IgM protein from anti-mu-chain Sepharose. Discrepancies between enzyme immunoassay and radioimmunoassay procedures for anti-HBc (Corzyme and Corab, respectively: Abbott Laboratories, North Chicago, Ill.) appear to be due to the relative sensitivity of the enzyme immunoassay for IgM anti-HBc (sevenfold greater than the radioimmunoassay using a specific panel). The biological basis for the occurrence of low levels of nonspecific IgM anti-HBc reactivity in individuals not previously exposed to HBV remains to be elucidated.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 2037679      PMCID: PMC269827          DOI: 10.1128/jcm.29.3.605-610.1991

Source DB:  PubMed          Journal:  J Clin Microbiol        ISSN: 0095-1137            Impact factor:   5.948


  16 in total

1.  Improvement in the specificity of assays for detection of antibody to hepatitis B core antigen.

Authors:  J A Weare; E F Robertson; G Madsen; R Hu; R H Decker
Journal:  J Clin Microbiol       Date:  1991-03       Impact factor: 5.948

2.  Purification of human plasma alpha 2 macroglobulin and alpha 1 proteinase inhibitor using zinc chelate chromatography.

Authors:  T Kurecki; L F Kress; M Laskowski
Journal:  Anal Biochem       Date:  1979-11-01       Impact factor: 3.365

3.  Cleavage of structural proteins during the assembly of the head of bacteriophage T4.

Authors:  U K Laemmli
Journal:  Nature       Date:  1970-08-15       Impact factor: 49.962

4.  Antibody to hepatitis B core antigen as a paradoxical marker for non-A, non-B hepatitis agents in donated blood.

Authors:  D E Koziol; P V Holland; D W Alling; J C Melpolder; R E Solomon; R H Purcell; L M Hudson; F J Shoup; H Krakauer; H J Alter
Journal:  Ann Intern Med       Date:  1986-04       Impact factor: 25.391

5.  Hepatitis B virus antibody in blood donors and the occurrence of non-A, non-B hepatitis in transfusion recipients. An analysis of the Transfusion-Transmitted Viruses Study.

Authors:  C E Stevens; R D Aach; F B Hollinger; J W Mosley; W Szmuness; R Kahn; J Werch; V Edwards
Journal:  Ann Intern Med       Date:  1984-12       Impact factor: 25.391

6.  Epidemiological analysis of the significance of low-positive test results for antibody to hepatitis B surface and core antigens.

Authors:  S C Hadler; B L Murphy; C A Schable; W L Heyward; D P Francis; M A Kane
Journal:  J Clin Microbiol       Date:  1984-04       Impact factor: 5.948

7.  Antibodies to hepatitis B surface antigen as the sole hepatitis B marker in hospital personnel.

Authors:  H A Kessler; A A Harris; J A Payne; E Hudson; B Potkin; S Levin
Journal:  Ann Intern Med       Date:  1985-07       Impact factor: 25.391

8.  Acridinium esters as high-specific-activity labels in immunoassay.

Authors:  I Weeks; I Beheshti; F McCapra; A K Campbell; J S Woodhead
Journal:  Clin Chem       Date:  1983-08       Impact factor: 8.327

9.  Antibody to hepatitis B surface antigen in nonprimate animal species.

Authors:  J H Hoofnagle; D F Schafer; P Ferenci; J G Waggoner; J Vergalla; M April; L Phillips
Journal:  Gastroenterology       Date:  1983-06       Impact factor: 22.682

10.  The nucleocapsid of hepatitis B virus is both a T-cell-independent and a T-cell-dependent antigen.

Authors:  D R Milich; A McLachlan
Journal:  Science       Date:  1986-12-12       Impact factor: 47.728

View more
  3 in total

1.  Improvements in detection of antibody to hepatitis B core antigen by treating specimens with reducing agent in an automated microparticle enzyme immunoassay.

Authors:  A M Spronk; L Schmidt; C Krenc; L Pavlis-Jenkins; J Brady; S Taskar; L Angus-Finn; L Mimms
Journal:  J Clin Microbiol       Date:  1991-03       Impact factor: 5.948

2.  Novel double-antigen sandwich immunoassay for human hepatitis B core antibody.

Authors:  An Li; Quan Yuan; Zhiyin Huang; Jian Fan; Ruyi Guo; Bin Lou; Qin Zheng; Shengxiang Ge; Yixin Chen; Zhijun Su; Anthony E T Yeo; Yu Chen; Jun Zhang; Ningshao Xia
Journal:  Clin Vaccine Immunol       Date:  2010-01-27

Review 3.  Immunodiagnosis of viral hepatitides A to E and non-A to -E.

Authors:  G Yang; G N Vyas
Journal:  Clin Diagn Lab Immunol       Date:  1996-05
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.